UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) | --- | |-------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 001-36833 91-1949078 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification Number) Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock,par value $0.001 per share VNRX NYSE American, LLC FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, ...

Conference call to discuss financial and operational results scheduled forFriday, November 15 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev.  , Nov. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2024. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be f ...

Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., Nov. 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2024, in addition to providing a business update. Details of this event can be found below.Event: VolitionRx Limited Third Quarter 2024 Earnings and Busine ...

HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Timothy Still, Chairman of Volition Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his ...

HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report, from its 'NETs in sepsis management' symposium at ESICM Lives 2024 last month, which concluded that Nu.Q® NETs could be used to predict patients at greater risk of deteriorating from sepsis.The symposium explored research findings from three large, independent studies carried out at centers of excellence in France, Germany, and the Netherlands, i ...

Given the extensive size and scope of the three independent studies on the potential use of Nu.Q® NETs in sepsis management, which included over 3000 patients and more than 14,000 patient samples, the webinar aims to provide stakeholders with a comprehensive understanding of the data and offer insights into how Volition's nucleosome quantification technology could be used in clinical practice. The webinar takes place on Monday, October 21, at 10:00 AM U.S. Eastern Time and will include updates from Volition ...

HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The session, entitled 'NETs: Casting a new light on sepsis management', will take place at 12 ...

HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of ...

VolitionRx Limited (NYSE:VNRX) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing and Communications Officer Cameron Reynolds - President and CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Small-Cap Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the VolitionRx Li ...